J&J’s Oral IL-23R Blocker Sets New Standard in Plaque Psoriasis, Beating BMS’ Sotyktu
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’ Sotyktu at clearing skin and easing symptom severity in patients with plaque psoriasis.
J&J’s Oral IL-23R Blocker Sets New Standard in Plaque Psoriasis, Beating BMS’ Sotyktu Read More »
